Izabella Zathureczky, MD
Internal Medicine · Lawrenceville, NJNPI 1174513345
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 273 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $762 and has fallen 53.7% since, to $353 in 2025.
Across 273 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$630
- Bayer$495
- Astellas Pharma US Inc$475
- Novo Nordisk$471
- GSK$466
- Boehringer Ingelheim$171
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,60895%
- Education$1715%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $630 |
| Bayer | 33 | $495 |
| Astellas Pharma US Inc | 30 | $475 |
| Novo Nordisk | 39 | $471 |
| GSK | 31 | $466 |
| Boehringer Ingelheim | 11 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $164 |
| Kowa Pharmaceuticals America, Inc. | 12 | $162 |
| Sanofi-aventis U.S. LLC | 10 | $159 |
| Lilly USA, LLC | 10 | $133 |
| Exact Sciences | 5 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| AstraZeneca | 5 | $66 |
| Abbott | 3 | $52 |
| Merck | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Pfizer | 1 | $13 |
| Bausch Health US, LLC | 1 | $12 |
| Amgen | 1 | $12 |
How this compares
$3,779 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $88,210 |
| JardianceEmpagliflozin | 66 | $66,296 |
| ForteoTeriparatide | 12 | $50,357 |
| EliquisApixaban | 43 | $48,281 |
| RybelsusSemaglutide | 31 | $44,314 |
| TrulicityDulaglutide | 12 | $32,083 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $31,667 |
| CreonLipase/Protease/Amylase | 19 | $25,511 |
| MyrbetriqMirabegron | 31 | $21,256 |
| LinzessLinaclotide | 16 | $15,144 |
| TrintellixVortioxetine Hydrobromide | 11 | $11,088 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $10,381 |
| ViberziEluxadoline | 13 | $9,959 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $8,260 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 24 | $7,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $471 | $132,52495 claims |
| Lilly USA, LLCForteo, Trulicity | $133 | $82,44024 claims |
| Boehringer IngelheimJardiance | $171 | $66,29666 claims |
| AbbVieCreon, Linzess, Viberzi, Synthroid | $630 | $52,69283 claims |
| PfizerEliquis | $13 | $48,28143 claims |
| MerckJanumet | $30 | $31,66728 claims |
| Astellas Pharma US IncMyrbetriq | $475 | $21,25631 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $164 | $11,08811 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $159 | $10,38111 claims |
| GSKIncruse Ellipta | $466 | $4,07113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Lawrenceville
- Mahmood SiddiqueLawrenceville$110K
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.